Alglucosidase alfa 1.9g/1litre infusion bags Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

alglucosidase alfa 1.9g/1litre infusion bags

special order - alglucosidase alfa - infusion - 1.9mg/1ml

Alglucosidase alfa 1.85g/1litre infusion bags Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

alglucosidase alfa 1.85g/1litre infusion bags

special order - alglucosidase alfa - infusion - 1.85mg/1ml

Alglucosidase alfa 2.2g/1litre infusion bags Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

alglucosidase alfa 2.2g/1litre infusion bags

special order - alglucosidase alfa - infusion - 2.2mg/1ml

Alglucosidase alfa 2.1g/1litre infusion bags Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

alglucosidase alfa 2.1g/1litre infusion bags

special order - alglucosidase alfa - infusion - 2.1mg/1ml

Alglucosidase alfa 2g/1litre infusion bags Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

alglucosidase alfa 2g/1litre infusion bags

special order - alglucosidase alfa - infusion - 2mg/1ml

מיוזיים Израиль - иврит - Ministry of Health

מיוזיים

sanofi israel ltd - alglucosidase alfa - אבקה להכנת תרכיז לאינפוזיה - alglucosidase alfa 50 mg/vial - alglucosidase alfa - alglucosidase alfa - myozyme is indicated for long-term enzyme replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). the benefits of myozyme in patients with late-onset pompe disease have not been established.

Myozyme Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

myozyme

pharmacy retailing (nz) ltd t/a healthcare logistics - alglucosidase alfa 52.5mg;  ;  ;   - powder for infusion concentrate - 50 mg/10ml - active: alglucosidase alfa 52.5mg       excipient: dibasic sodium phosphate heptahydrate mannitol monobasic sodium phosphate monohydrate nitrogen polysorbate 80 - myozyme is indicated for the long - term treatment of patients with a confirmed diagnosis of pompe disease (acid alfa - glucosidase deficiency).

Nexviadyme Европейский союз - испанский - EMA (European Medicines Agency)

nexviadyme

sanofi b.v. - avalglucosidase alfa - enfermedad de almacenamiento de glucógeno tipo ii - otros tracto alimentario y metabolismo de los productos, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Myozyme Европейский союз - мальтийский - EMA (European Medicines Agency)

myozyme

sanofi b.v. - alglucosidase alfa - mard tal-Ħażna tal-glukoġen tat-tip ii - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - myozyme huwa indikat għal terapija s-sostituzzjoni ta ' l-enżima fit-tul (ert) fil-pazjenti bl-djanjosi konfermata tal-marda ta ' l-pompe (aċidu-α-glucosidase defiċjenza). f'pazjenti b'bidu tard tal-marda marda ta ' pompe l-evidenza tal-effikaċja hija limitata.

Myozyme Европейский союз - датский - EMA (European Medicines Agency)

myozyme

sanofi b.v. - alglucosidase alfa - glycogen opbevaring sygdom type ii - andre alimentary tract and metabolism produkter, - myozyme er indiceret til langsigtet enzymbytningsbehandling (ert) hos patienter med en bekræftet diagnose af pompe-sygdom (syre-a-glucosidase mangel). hos patienter med sent indsættende pompes sygdom, dokumentation af effekten er begrænset.